Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsLupinlaboratories

    Jump to

    • Expect margins to improve by 100bps in FY13: Lupin

      In an interview to CNBC-TV18, Lupin Managing Director Kamal K. Sharma analysed the performance of the company in the second quarter.

    • Lupin says working on 10 promising lead molecules

      Lupin has always been very shy in discussing their drug discovery pipeline. However, in an exclusive interview with CNBC-TV18, Dr Kamal Sharma, said that the company is excited about the R&D pipeline, which has 10 lead molecules, and could be potential out-licencing targets by next year.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347